Lyell Immunopharma, Inc.
LYEL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $167,347 | $486,907 | $857,368 | $1,878,792 |
| - Cash | $105,597 | $145,647 | $123,554 | $293,828 |
| + Debt | $58,968 | $63,167 | $67,702 | $67,819 |
| Enterprise Value | $120,718 | $404,427 | $801,516 | $1,652,783 |
| Revenue | $61 | $130 | $84,683 | $10,650 |
| % Growth | -53.1% | -99.8% | 695.1% | – |
| Gross Profit | $61 | $130 | $84,683 | $10,650 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$200,643 | -$226,758 | -$169,038 | -$201,152 |
| % Margin | -328,923% | -174,429.2% | -199.6% | -1,888.8% |
| Net Income | -$342,994 | -$234,632 | -$183,118 | -$250,219 |
| % Margin | -562,285.2% | -180,486.2% | -216.2% | -2,349.5% |
| EPS Diluted | -1.31 | -0.935 | -0.741 | -1.031 |
| % Growth | -40.1% | -26.1% | 28.1% | – |
| Operating Cash Flow | -$162,394 | -$163,694 | -$169,555 | -$126,249 |
| Capital Expenditures | -$464 | -$2,686 | -$24,276 | -$65,504 |
| Free Cash Flow | -$162,858 | -$166,380 | -$193,831 | -$191,753 |